Researchers have confirmed in a new study that common nasal diseases, such as allergic rhinitis and nasal polyps, are highly ...

The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...

Patients with bronchiectasis from different European countries have strikingly different variations in microbiome composition and resistome.

Among children studied, causes of bronchiectasis were most commonly post-infective (31%), primary and secondary immunodeficiencies (19%), and genetic (13%). Children and teens with bronchiectasis and ...

New Jersey-based company, Insmed Incorporated (NASDAQ:INSM), is a global biopharmaceutical company developing life‑altering ...

NTM Info & Research is a national nonprofit dedicated to supporting patients with the progressive lung disease. The nonprofit ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

The Bronchiectasis and NTM Association joins other global patient advocacy organizations, professional societies, and lung health experts for the third annual World NTM Awareness Day on Monday, August ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

How can we address the challenges associated with the highly heterogeneous nature of bronchiectasis? This review aimed to discuss the concepts of phenotype and endotype and the recent advancements in ...

Minnesota-based company, Electromed, Inc. (NYSE:ELMD), develops, manufactures, and markets the SmartVest System, a ...

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key." ...